In ever-changing field environments, conditions can shift rapidly, eroding the best-laid plans with little time to react.

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

My coding skills leave something to be desired. I never stuck with the instructional books and guides long enough to truly create the kinds of apps and programs I wanted to see. AI chatbots powered by ...

TIOBE Index for December 2025: Top 10 Most Popular Programming Languages Your email has been sent December’s TIOBE Index lands with a quieter top tier but a livelier shuffle just beneath it. The main ...

Jan. 4, 2026 Researchers using China’s “artificial sun” fusion reactor have broken through a long-standing density barrier in fusion plasma. The experiment confirmed that plasma can remain stable even ...

AI tools promise that anyone can build apps, so I put that claim to the test. After a few minor bumps, I built a custom ...